Kodiak Sciences (KOD) Retained Earnings (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Retained Earnings came in at -$1.6 billion in Q1 2026, down 16.64% YoY from -$1.9 billion in Q1 2025, and down 3.73% on a QoQ basis from -$1.6 billion in Q4 2025.
Analysis
Kodiak Sciences (KOD) Retained Earnings (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Retained Earnings data on file, last reported at -$1.6 billion in Q1 2026.
- Quarterly Retained Earnings fell 16.64% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 16.64% YoY) and the FY2025 annual result came in at -$1.6 billion, down 17.31% from the prior year.
- Retained Earnings fell to -$1.6 billion in Q1 2026, from -$1.6 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1.3 million in Q4 2022 to a low of -$1.6 billion in Q1 2026.
- A 5-year average of -$1.1 billion and a median of -$1.2 billion in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 3633022.22% — and 2024, when it fell 15.29%.
- Tracing KOD's Retained Earnings over 5 years: stood at -$1.3 million in 2022, then slumped by 88081.41% to -$1.2 billion in 2023, then slipped by 15.29% to -$1.3 billion in 2024, then declined by 17.31% to -$1.6 billion in 2025, then dropped by 3.73% to -$1.6 billion in 2026.
- The last three Retained Earnings figures came in at -$1.6 billion (Q1 2026), -$1.6 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | -1.68 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.68 Bn |
| Mar 31, 2026 | -1.62 Bn |
| Dec 31, 2025 | -1.56 Bn |
| Sep 30, 2025 | -1.50 Bn |
| Jun 30, 2025 | -1.44 Bn |
| Mar 31, 2025 | -1.39 Bn |
| Dec 31, 2024 | -1.33 Bn |
| Sep 30, 2024 | -1.28 Bn |
| Jun 30, 2024 | -1.24 Bn |
| Mar 31, 2024 | -1.20 Bn |
| Dec 31, 2023 | -1.15 Bn |
| Sep 30, 2023 | -1.09 Bn |
| Jun 30, 2023 | -1.04 Bn |
| Mar 31, 2023 | -962.82 Mn |
| Dec 31, 2022 | -892.04 Mn |
| Sep 30, 2022 | -821.59 Mn |
| Jun 30, 2022 | -744.55 Mn |
| Mar 31, 2022 | -653.93 Mn |
| Dec 31, 2021 | -558.22 Mn |
| Sep 30, 2021 | -465.05 Mn |